线粒体向的铜输送用于基于cuproptosis的协同癌症治疗
Jinpeng Deng1, Huilan Zhuang1, Sijie Shao1
1The Straits Laboratory of Flexible Electronics (SLoFE), Straits Institute of Flexible Electronics (SIFE Future Technologies), Fujian Normal University, Fuzhou, Fujian, 350117, China.
一种新的纳米平台 (ZCProP) 将铜离子和奇异传递给线粒体,触发细胞亡 (编程细胞死亡) 和铁亡,以增强癌症治疗. 这种方法为癌症治疗提供了一个新的策略.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 癌症生物学 癌症生物学
背景情况:
- 细胞死亡途径库普罗托斯与线粒体呼吸和TCA循环蛋白有关.
- 针对线粒体的铜离子释放至关重要,但对于诱导cuproptosis具有挑战性.
- 现有的癌症治疗需要新的策略来提高疗效.
研究的目的:
- 设计一个纳米平台,以向线粒体输送铜离子和神奇物质.
- 研究这个纳米平台在触发cuproptosis和ferroptosis方面的治疗潜力.
- 探索一种基于双细胞死亡诱导的新型癌症治疗策略.
主要方法:
- 基于金属有机框架的纳米平台 (ZCProP) 的开发.
- 线粒体向和ATP/pH响应的Cu2+和prodigiosin的释放.
- 通过脂质化蛋白聚合和Fe-S集群损失对cuproptosis诱导的评估.
- 评估线粒体功能障碍,DNA损伤和谷氨耗尽.
- 对细胞死亡途径 (包括铁亡) 的协同效应的研究.
主要成果:
- ZCProP成功地将Cu2+和奇异传递到线粒体.
- 纳米平台通过破坏TCA循环蛋白和Fe-S集群来诱导cuproptosis.
- 2+和奇异的协同作用增强了线粒体功能障碍和DNA损伤.
- 通过ZCProP减少谷氨酸,通过抑制GPX4促进了cuproptosis和诱导ferroptosis.
- 该纳米平台显示出显著的治疗效果,具有出色的生物相容性.
结论:
- ZCProP纳米平台在线粒体中提供了有针对性的,响应性的载荷释放.
- 它通过协同的机制有效诱导cuproptosis和ferroptosis.
- 这种双细胞死亡诱导策略对新的癌症治疗范式有希望.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
09:48Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
